메뉴 건너뛰기




Volumn 26, Issue 5, 2006, Pages 473-480

Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis

Author keywords

Ankylosing; Anti infliximab; Infliximab; Tumour necrosis factor alpha (TNF )

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; DRUG ANTIBODY; HLA B27 ANTIGEN; HUMAN ANTIBODY; HUMAN MOUSE ANTIBODY; INFLIXIMAB; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

EID: 33644625163     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-005-0085-0     Document Type: Article
Times cited : (23)

References (35)
  • 1
    • 0036806622 scopus 로고    scopus 로고
    • The TNF-TNF receptor system
    • Hehlgans T, Mannel DN (2002) The TNF-TNF receptor system. Biol Chem 383:1581-1585
    • (2002) Biol Chem , vol.383 , pp. 1581-1585
    • Hehlgans, T.1    Mannel, D.N.2
  • 2
    • 17944381638 scopus 로고    scopus 로고
    • Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation
    • Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ et al (2001) Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15:533-543
    • (2001) Immunity , vol.15 , pp. 533-543
    • Ruuls, S.R.1    Hoek, R.M.2    Ngo, V.N.3    McNeil, T.4    Lucian, L.A.5    Janatpour, M.J.6
  • 4
    • 0036121098 scopus 로고    scopus 로고
    • TNF receptor subtype signalling: Differences and cellular consequences
    • MacEwan DJ (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14:477-492
    • (2002) Cell Signal , vol.14 , pp. 477-492
    • MacEwan, D.J.1
  • 5
    • 0037204948 scopus 로고    scopus 로고
    • TNF-R1 signaling: A beautiful pathway
    • Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296(5573):1634-1635
    • (2002) Science , vol.296 , Issue.5573 , pp. 1634-1635
    • Chen, G.1    Goeddel, D.V.2
  • 6
    • 0642366755 scopus 로고    scopus 로고
    • Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
    • Mikuls TR, Weaver AL (2003) Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 5:270-277
    • (2003) Curr Rheumatol Rep , vol.5 , pp. 270-277
    • Mikuls, T.R.1    Weaver, A.L.2
  • 8
    • 0041826789 scopus 로고    scopus 로고
    • Effectiveness of psoriatic arthritis therapies
    • Gladman DD (2003) Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 33:29-37
    • (2003) Semin Arthritis Rheum , vol.33 , pp. 29-37
    • Gladman, D.D.1
  • 9
    • 0038302429 scopus 로고    scopus 로고
    • Treatment of primary systemic vasculitis with TNF alpha-antagonists
    • Gause A, Arbach O, Lamprecht P (2003) Treatment of primary systemic vasculitis with TNF alpha-antagonists. Z Rheumatol 62:228-234
    • (2003) Z Rheumatol , vol.62 , pp. 228-234
    • Gause, A.1    Arbach, O.2    Lamprecht, P.3
  • 10
    • 2642513223 scopus 로고    scopus 로고
    • Developing a new generation of TNF-α antagonists for the treatment of rheumatoid arthritis
    • Fleischmann R, Shealy D (2003) Developing a new generation of TNF-α antagonists for the treatment of rheumatoid arthritis. Mol Interv 3:310-318
    • (2003) Mol Interv , vol.3 , pp. 310-318
    • Fleischmann, R.1    Shealy, D.2
  • 11
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
    • ATTRACT Study Group
    • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 354(9194):1932-1939
    • (1999) Lancet , vol.354 , Issue.9194 , pp. 1932-1939
    • Maini, R.1    St Clair, E.W.2    Breedveld, F.3    Furst, D.4    Kalden, J.5    Weisman, M.6
  • 12
    • 1542369183 scopus 로고    scopus 로고
    • Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
    • Sandborn WJ (2003) Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 5:501-505
    • (2003) Curr Gastroenterol Rep , vol.5 , pp. 501-505
    • Sandborn, W.J.1
  • 13
    • 4544317926 scopus 로고    scopus 로고
    • Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab
    • Chew AL, Bennett A, Smith CH, Barker J, Kirkham B (2004) Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 151:492-496
    • (2004) Br J Dermatol , vol.151 , pp. 492-496
    • Chew, A.L.1    Bennett, A.2    Smith, C.H.3    Barker, J.4    Kirkham, B.5
  • 14
    • 0034729950 scopus 로고    scopus 로고
    • Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
    • Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385-390
    • (2000) Lancet , vol.356 , pp. 385-390
    • Mease, P.J.1    Goffe, B.S.2    Metz, J.3    VanderStoep, A.4    Finck, B.5    Burge, D.J.6
  • 15
    • 0042072982 scopus 로고    scopus 로고
    • Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial
    • Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48:2224-2233
    • (2003) Arthritis Rheum , vol.48 , pp. 2224-2233
    • Braun, J.1    Brandt, J.2    Listing, J.3    Zink, A.4    Alten, R.5    Burmester, G.6
  • 16
    • 0037029430 scopus 로고    scopus 로고
    • Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicentre trial
    • Braun J, Brandt J, Listing J, Zink A, Alten R, Gromnica-Ihle E et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359(9313):1187-1193
    • (2002) Lancet , vol.359 , Issue.9313 , pp. 1187-1193
    • Braun, J.1    Brandt, J.2    Listing, J.3    Zink, A.4    Alten, R.5    Gromnica-Ihle, E.6
  • 17
    • 0036852331 scopus 로고    scopus 로고
    • Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study
    • Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E et al (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41:1280-1285
    • (2002) Rheumatology , vol.41 , pp. 1280-1285
    • Breban, M.1    Vignon, E.2    Claudepierre, P.3    Devauchelle, V.4    Wendling, D.5    Lespessailles, E.6
  • 18
    • 0042887352 scopus 로고    scopus 로고
    • Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease?
    • Baeten D, Kruithof E, Bosch F, Van den Bossche N, Herssens A, Mielants H et al (2003) Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62:829-834
    • (2003) Ann Rheum Dis , vol.62 , pp. 829-834
    • Baeten, D.1    Kruithof, E.2    Bosch, F.3    Van Den Bossche, N.4    Herssens, A.5    Mielants, H.6
  • 19
    • 0043203001 scopus 로고    scopus 로고
    • Severe neutropenia and thrombocytopenia associated with infliximab
    • Vidal F, Fontova R, Richart C (2003) Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 139:E238-E239
    • (2003) Ann Intern Med , vol.139
    • Vidal, F.1    Fontova, R.2    Richart, C.3
  • 20
    • 0037434552 scopus 로고    scopus 로고
    • Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease
    • Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A et al (2003) Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608
    • (2003) N Engl J Med , vol.348 , pp. 601-608
    • Baert, F.1    Noman, M.2    Vermeire, S.3    Van Assche, G.4    D'Haens, G.5    Carbonez, A.6
  • 21
    • 0033763979 scopus 로고    scopus 로고
    • Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials
    • Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383-2390
    • (2000) Arthritis Rheum , vol.43 , pp. 2383-2390
    • Charles, P.J.1    Smeenk, R.J.2    De Jong, J.3    Feldmann, M.4    Maini, R.N.5
  • 22
    • 0038109994 scopus 로고    scopus 로고
    • Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: A prospective cohort study
    • Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N et al (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125:32-39
    • (2003) Gastroenterology , vol.125 , pp. 32-39
    • Vermeire, S.1    Noman, M.2    Van Assche, G.3    Baert, F.4    Van Steen, K.5    Esters, N.6
  • 23
    • 16344383360 scopus 로고    scopus 로고
    • Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: A two-year prospective study
    • Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535-R543
    • (2004) Arthritis Res Ther , vol.6
    • Ferraro-Peyret, C.1    Coury, F.2    Tebib, J.G.3    Bienvenu, J.4    Fabien, N.5
  • 24
    • 0026900423 scopus 로고
    • The clinical significance of HAMA in patients treated with mouse monoclonal antibodies
    • Frodin JE, Lefvert AK, Mellstedt H (1992) The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 21:153-165
    • (1992) Cell Biophys , vol.21 , pp. 153-165
    • Frodin, J.E.1    Lefvert, A.K.2    Mellstedt, H.3
  • 25
    • 0033855859 scopus 로고    scopus 로고
    • Clinical trials of antibody therapy
    • Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy, Immunol Today 21:403-410
    • (2000) Immunol Today , vol.21 , pp. 403-410
    • Glennie, M.J.1    Johnson, P.W.2
  • 27
    • 0028579768 scopus 로고
    • A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index
    • Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
    • (1994) J Rheumatol , vol.21 , pp. 2281-2285
    • Calin, A.1    Garrett, S.2    Whitelock, H.3    Kennedy, L.G.4    O'Hea, J.5    Mallorie, P.6
  • 28
    • 0030074829 scopus 로고    scopus 로고
    • An update on the bath ankylosing spondylitis disease activity and functional indices (BASDAI, BASFI): Excellent Cronbach's alpha scores
    • Biasi D, Carletto A, Caramaschi P, Bambara LM (1996) An update on the bath ankylosing spondylitis disease activity and functional indices (BASDAI, BASFI): excellent Cronbach's alpha scores. J Rheumatol 23:407-408
    • (1996) J Rheumatol , vol.23 , pp. 407-408
    • Biasi, D.1    Carletto, A.2    Caramaschi, P.3    Bambara, L.M.4
  • 29
    • 0033984226 scopus 로고    scopus 로고
    • Development of a rapid, single-step procedure using protein G affinity chromatography to deplete fetal calf serum of its IgG and to isolate murine IgG1 monoclonal antibodies from supernatants of hybridoma cells
    • Aybay C, Imir T (2000) Development of a rapid, single-step procedure using protein G affinity chromatography to deplete fetal calf serum of its IgG and to isolate murine IgG1 monoclonal antibodies from supernatants of hybridoma cells. J Immunol Methods 233:77-81
    • (2000) J Immunol Methods , vol.233 , pp. 77-81
    • Aybay, C.1    Imir, T.2
  • 30
    • 3543106683 scopus 로고    scopus 로고
    • Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab
    • Miele E, Markowitz JE, Mamula P, Baldassano RN (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38:502-508
    • (2004) J Pediatr Gastroenterol Nutr , vol.38 , pp. 502-508
    • Miele, E.1    Markowitz, J.E.2    Mamula, P.3    Baldassano, R.N.4
  • 32
    • 0038476357 scopus 로고    scopus 로고
    • Immunogenicity of therapeutic monoclonal antibodies
    • Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172-179
    • (2003) Curr Opin Mol Ther , vol.5 , pp. 172-179
    • Pendley, C.1    Schantz, A.2    Wagner, C.3
  • 33
    • 0037234032 scopus 로고    scopus 로고
    • Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
    • Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U et al (2003) Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48:68-75
    • (2003) J Am Acad Dermatol , vol.48 , pp. 68-75
    • Gottlieb, A.B.1    Masud, S.2    Ramamurthi, R.3    Abdulghani, A.4    Romano, P.5    Chaudhari, U.6
  • 34
    • 0031660364 scopus 로고    scopus 로고
    • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
    • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563
    • (1998) Arthritis Rheum , vol.41 , pp. 1552-1563
    • Maini, R.N.1    Breedveld, F.C.2    Kalden, J.R.3    Smolen, J.S.4    Davis, D.5    Macfarlane, J.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.